New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
08:19 EDTBSXBoston Scientific to expand restructuring, sees cutting 900-1,000 jobs
The company announced earlier an expansion of its 2011 restructuring program. The company estimates that the Expansion will reduce gross annual pre-tax operating expenses by approximately $100M-$115M exiting 2013; and that the total 2011 restructuring program, including the Expansion, will reduce gross annual pre-tax operating expenses by approximately $340M-$375M exiting 2013. The company anticipates the reduction of 900 to 1,000 positions worldwide through a combination of employee attrition and targeted headcount reductions as a result of the Expansion. The company estimates that the implementation of the Expansion will result in total pre-tax charges of approximately $140M-$160M, and that approximately $100M-$120M of these charges will result in future cash outlays. The company estimates that the implementation of the Total Program will result in total pre-tax charges of approximately $300M-$355M, and that approximately $270M-$300M of these charges will result in future cash outlays.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:56 EDTBSXBoston Scientific initiated with a Hold at Needham
September 24, 2014
16:41 EDTBSXCourt says Boston Scientific breached license agreement
Boston Scientific disclosed in a regulatory filing that on September 24, following a jury verdict against Boston Scientific Corporation, the Montgomery County Circuit Court in Maryland entered a judgment that the company breached its license agreement with Mirowski Family Ventures and awarded damages of $308M. The company believes the facts and the law do not support the jury’s findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process.
September 23, 2014
16:09 EDTBSXBoston Scientific enrolls first patients in U.S. trial of Lotus Valve System
Boston Scientific has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement device that is both fully repositionable and retrievable prior to release. The primary endpoints of the study are Safety; composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications at 30 days. Efficacy; composite of all-cause mortality, disabling stroke or moderate or greater paravalvular aortic regurgitation at one year following procedure.
September 17, 2014
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use